JP2022537824A5 - - Google Patents
Info
- Publication number
- JP2022537824A5 JP2022537824A5 JP2021576275A JP2021576275A JP2022537824A5 JP 2022537824 A5 JP2022537824 A5 JP 2022537824A5 JP 2021576275 A JP2021576275 A JP 2021576275A JP 2021576275 A JP2021576275 A JP 2021576275A JP 2022537824 A5 JP2022537824 A5 JP 2022537824A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- receptor
- amino acid
- cancer
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025040192A JP2025106277A (ja) | 2019-06-26 | 2025-03-13 | Cd3抗原結合断片およびそれを含む組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962866746P | 2019-06-26 | 2019-06-26 | |
| US62/866,746 | 2019-06-26 | ||
| US202063041059P | 2020-06-18 | 2020-06-18 | |
| US63/041,059 | 2020-06-18 | ||
| PCT/US2020/039673 WO2020264200A1 (en) | 2019-06-26 | 2020-06-25 | Cd3 antigen binding fragments and compositions comprising same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025040192A Division JP2025106277A (ja) | 2019-06-26 | 2025-03-13 | Cd3抗原結合断片およびそれを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537824A JP2022537824A (ja) | 2022-08-30 |
| JP2022537824A5 true JP2022537824A5 (cg-RX-API-DMAC7.html) | 2023-06-30 |
| JP7651481B2 JP7651481B2 (ja) | 2025-03-26 |
Family
ID=74059962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576275A Active JP7651481B2 (ja) | 2019-06-26 | 2020-06-25 | Cd3抗原結合断片およびそれを含む組成物 |
| JP2025040192A Pending JP2025106277A (ja) | 2019-06-26 | 2025-03-13 | Cd3抗原結合断片およびそれを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025040192A Pending JP2025106277A (ja) | 2019-06-26 | 2025-03-13 | Cd3抗原結合断片およびそれを含む組成物 |
Country Status (18)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20260039804A (ko) * | 2017-12-21 | 2026-03-20 | 아뮤닉스 파마슈티컬스, 인크. | 유리 세그먼트 및 이것을 포함하는 결합 조성물 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| WO2020264200A1 (en) * | 2019-06-26 | 2020-12-30 | Amunix Pharmceuticals, Inc. | Cd3 antigen binding fragments and compositions comprising same |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| PH12022553407A1 (en) * | 2020-06-25 | 2024-04-22 | Amunix Pharmaceuticals Inc | Her-2 targeted bispecific compositions and methods for making and using the same |
| AU2021326469C1 (en) | 2020-08-11 | 2026-04-30 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| EP4058474B1 (en) * | 2020-08-20 | 2024-05-08 | A2 Biotherapeutics, Inc. | Compositions and methods for treating egfr positive cancers |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| WO2022170619A1 (en) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anti-cd3 antibodies and methods of use thereof |
| CN117616137A (zh) * | 2021-05-11 | 2024-02-27 | 佳努克斯治疗公司 | 靶向egfr和cd3的抗体及其用途 |
| AR125758A1 (es) | 2021-05-12 | 2023-08-09 | Janux Therapeutics Inc | Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras |
| EP4433096A1 (en) * | 2021-11-19 | 2024-09-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
| WO2023192973A1 (en) * | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| CN116063498A (zh) * | 2022-04-27 | 2023-05-05 | 博际生物医药科技(杭州)有限公司 | 单域抗Nectin-4抗体 |
| CN116724057A (zh) * | 2022-11-28 | 2023-09-08 | 浙江时迈药业有限公司 | 蛋白酶可切割的重组双特异性抗体和组合物及其用途 |
| JP7855148B2 (ja) | 2023-02-10 | 2026-05-07 | アムニクス ファーマシューティカルズ, インコーポレイテッド | 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法 |
| US20240400696A1 (en) | 2023-04-17 | 2024-12-05 | Amunix Pharmaceuticals, Inc. | Compositions targeting epidermal growth factor receptor and methods for making and using the same |
| WO2024220870A1 (en) * | 2023-04-19 | 2024-10-24 | The University Of Chicago | Antibody-targeted enzymatic chemoprotection |
| WO2024218715A1 (en) | 2023-04-19 | 2024-10-24 | Btl Healthcare Technologies A.S. | Culture media based on protein hydrolysate and a process for preparing thereof |
| US12668774B2 (en) | 2023-10-12 | 2026-06-30 | Btl Healthcare Technologies A.S. | Product, system and method of cell cultivation |
| KR20260114559A (ko) | 2023-12-08 | 2026-07-22 | 아뮤닉스 파마슈티컬스, 인크. | 프로테아제 활성화가능 사이토카인 및 이의 제조 및 사용 방법 |
| CN120230203A (zh) * | 2023-12-28 | 2025-07-01 | 四川思柏沃生物技术有限公司 | 抗cd3抗体及其用途 |
| WO2025220804A1 (ko) * | 2024-04-18 | 2025-10-23 | 주식회사 큐로셀 | Cd5에 대한 신규 항체 및 이의 용도 |
| WO2026024863A2 (en) | 2024-07-24 | 2026-01-29 | Amunix Pharmaceuticals, Inc. | Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists |
| WO2026136923A1 (en) * | 2024-12-20 | 2026-06-25 | Vir Biotechnology, Inc. | Therapeutic uses of her-2 targeted bispecific polypeptides |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| KR100945108B1 (ko) | 2001-06-13 | 2010-03-02 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (egfr)에 대한 인간모노클로날 항체 |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| US8236308B2 (en) * | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| EP2193149A1 (en) | 2007-10-02 | 2010-06-09 | Merck Patent GmbH | Crystalline egfr - matuzumab complex and matuzumab mimetics obtained thereof |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| PE20121539A1 (es) | 2009-06-08 | 2012-12-06 | Amunix Operating Inc | Polipeptidos de la hormona de crecimiento y metodos de preparacion |
| WO2010144508A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン(シャンハイ)コーポレイション リミテッド | 多重特異性Fab融合タンパク質および使用法 |
| ES2770501T3 (es) | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| US20160326249A1 (en) * | 2014-01-15 | 2016-11-10 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| MY195059A (en) * | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| KR20260039804A (ko) * | 2017-12-21 | 2026-03-20 | 아뮤닉스 파마슈티컬스, 인크. | 유리 세그먼트 및 이것을 포함하는 결합 조성물 |
| WO2020264200A1 (en) * | 2019-06-26 | 2020-12-30 | Amunix Pharmceuticals, Inc. | Cd3 antigen binding fragments and compositions comprising same |
| EP4058466A1 (en) * | 2019-11-13 | 2022-09-21 | Amunix Pharmaceuticals, Inc. | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
-
2020
- 2020-06-25 WO PCT/US2020/039673 patent/WO2020264200A1/en not_active Ceased
- 2020-06-25 CA CA3143519A patent/CA3143519A1/en active Pending
- 2020-06-25 BR BR112021026089A patent/BR112021026089A2/pt unknown
- 2020-06-25 US US17/621,993 patent/US20230121775A1/en active Pending
- 2020-06-25 AU AU2020308868A patent/AU2020308868A1/en active Pending
- 2020-06-25 JP JP2021576275A patent/JP7651481B2/ja active Active
- 2020-06-25 EP EP20833432.6A patent/EP3990497A4/en active Pending
- 2020-06-25 PH PH1/2021/500051A patent/PH12021500051A1/en unknown
- 2020-06-25 KR KR1020227002573A patent/KR20220038068A/ko active Pending
- 2020-06-25 PE PE2021002228A patent/PE20220600A1/es unknown
- 2020-06-25 CR CR20210628A patent/CR20210628A/es unknown
- 2020-06-25 CN CN202080061316.5A patent/CN115175933A/zh active Pending
- 2020-06-25 MX MX2021015880A patent/MX2021015880A/es unknown
- 2020-08-19 US US16/996,899 patent/US20210054077A1/en not_active Abandoned
-
2021
- 2021-12-15 DO DO2021000264A patent/DOP2021000264A/es unknown
- 2021-12-19 IL IL289102A patent/IL289102A/en unknown
- 2021-12-22 CL CL2021003448A patent/CL2021003448A1/es unknown
-
2022
- 2022-01-19 CO CONC2022/0000406A patent/CO2022000406A2/es unknown
- 2022-01-25 EC ECSENADI20225986A patent/ECSP22005986A/es unknown
-
2025
- 2025-03-13 JP JP2025040192A patent/JP2025106277A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023229555B2 (en) | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy | |
| JP7148539B2 (ja) | 免疫抱合体 | |
| TWI890655B (zh) | 改良之抗原結合受體 | |
| JP7857236B2 (ja) | 免疫活性化Fcドメイン結合分子 | |
| US12522638B2 (en) | IL12 receptor agonists and methods of use thereof | |
| CN115023444A (zh) | 新型il2激动剂及其使用方法 | |
| CN112638950B (zh) | 一种双特异性抗体 | |
| EP3990497A1 (en) | Cd3 antigen binding fragments and compositions comprising same | |
| WO2023045977A1 (zh) | 白介素2突变体以及其融合蛋白 | |
| KR20180057720A (ko) | 다가 Fv 항체 | |
| JP2023512452A (ja) | Bcma指向性細胞免疫療法組成物および方法 | |
| CN117836328A (zh) | 一种多特异性抗原结合蛋白及其应用 | |
| JP2022553292A5 (cg-RX-API-DMAC7.html) | ||
| WO2022148853A1 (en) | Immunoconjugates | |
| JP2024537096A (ja) | がんの治療のための代替的なPD1-IL7vイムノコンジュゲート | |
| CN115052897B (zh) | PLAP-CD3ε双特异性抗体 | |
| WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
| US20250333464A1 (en) | Il10 agonists and methods of use thereof | |
| CN118726265A (zh) | 自分泌多特异性纳米抗体的工程化免疫细胞 | |
| US20250115657A1 (en) | Bispecific FC Fusion Proteins with sPD-1 and IL-15 | |
| CN120826234A (zh) | 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法 | |
| RU2022101308A (ru) | Антигенсвязывающие фрагменты для cd3 и композиции, содержащие их | |
| WO2024199458A1 (en) | Il-2 variants with improved stability and compositions thereof | |
| US20240270836A1 (en) | Il12 receptor agonists and methods of use thereof | |
| WO2025064716A1 (en) | T-cell modulatory polypeptides and methods of use thereof |